Genetic Study in Alpha 1 Antitrypsin Deficiency
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
Recruiting
Phase 4
Interventional Study
Alpha 1-Antitrypsin
COPD
Antibody Deficiency
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 30 (estimated)
- Sponsor
- University of Alabama at Birmingham · Other
Who this trial is looking for
This trial is looking for adults who have a specific genetic mutation related to alpha 1 antitrypsin deficiency. Participants will receive a pneumonia vaccine and scientists will observe their immune responses based on their history of COPD flare-ups over the past year.
Are You a Good Fit for This Trial?
You may be able to join if
- I have a genetic mutation related to alpha 1 antitrypsin deficiency
- I have had no COPD flare-ups or 2 or more in the last year
- I have not received a pneumonia conjugate vaccine in the past 5 years
- I have only received a pneumococcal polysaccharide vaccine in the past
You may not be able to join if
- I have received a pneumonia conjugate vaccine in the past 5 years
- I have a known allergy or severe reaction to pneumonia vaccines
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections.
To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between part…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults who are heterozygous for a SERPINA1 Z allele
* Have either had no COPD exacerbations or 2 or more exacerbations in the previous year
* Has not received a pneumococcal conjugate vaccine within the past 5 years, or has only received the pneumococcal polysaccharide vaccine…
Contacts